GSTM1 and anemia: Eleven (50%) women experienced one or more grade 3 or greater adverse events (AEs) after study entry, including five (23%) cases of grade 3 anemia (Hb 6.5 to <8.5 g/dL) at study entry and two (9%) postpartum.